Arimoclomol Fails to Show Efficacy in Phase 3 Trial, Topline Data Show

Arimoclomol Fails to Show Efficacy in Phase 3 Trial, Topline Data Show

293996

Arimoclomol Fails to Show Efficacy in Phase 3 Trial, Topline Data Show

A Phase 3 clinical trial evaluating Orphazyme’s investigational oral therapy arimoclomol for amyotrophic lateral sclerosis (ALS) has failed to meet its primary and key secondary goals. While no safety issues were reported in the trial (NCT03491462), arimoclomol did not significantly extend patients’ lives nor delay the progression of disability among people with the disease. Topline data will be presented this week at the European Network to Cure ALS (ENCALS) meeting, to be held virtually May 12-14.…

You must be logged in to read/download the full post.